Jason Harris
Articles
CheckMate 648 Update Showcases Long-Term Survival Benefit With Frontline Nivolumab in ESCC
January 24, 2023
Article
The median overall survival with nivolumab plus chemotherapy was 12.8 months, vs 10.7 months with chemotherapy alone, in patients with treatment-naïve advanced esophageal squamous cell carcinoma.
During End-of-Life Cancer Care, Patients of Color Less Likely To Receive Opioid Treatment
January 14, 2023
Article
Findings showed that Black patients were 4.3 percentage points less likely to receive any opioid and 3.1 percentage points less likely to receive long-acting opioids near end-of-life compared with White patients.
Glofitamab Induces Promising Complete Response Rate in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
January 04, 2023
Article
Glofitamab, an investigational CD20xCD3 T-cell engaging bispecific antibody, elicited encouraging response rates in patients with relapsed/refractory diffuse large B-cell lymphoma in a phase 1/2 study.
Enzalutamide Inspires Meaningful Delay in PSA Progression For Patients With PSA-Recurrent High-Risk Prostate Cancer
December 03, 2022
Article
Combining enzalutamide with salvage radiation therapy helped delay prostate-specific antigen progression in patients with PSA-recurrent, high-risk prostate cancer.
DCVax-L Shows Survival Benefit in Newly Diagnosed and Recurrent Glioblastoma
November 23, 2022
Article
The autologous tumor lysate-loaded dendritic cell vaccination reduced the risk of death for patients with newly diagnosed glioblastoma by 20%.
Osimertinib Still Holds The Crown in EGFR-Mutated Non-Small Cell Lung Cancer
November 19, 2022
Article
As of November 2022, osimertinib is the preferred choice for the frontline treatment of EGFR-mutated non-small cell lung cancer. However, some experts believe that combination chemotherapy plus EGFR TKI will become a standard frontline treatment.
Chemoradiotherapy Plus Capecitabine Delivers Superior Failure-Free Survival in High-Risk Nasopharyngeal Carcinoma
November 06, 2022
Article
At a 5-year follow-up, the failure-free survival rate with capecitabine was 83.3% vs 72.2% with observation.
Pembrolizumab Induces Encouraging Outcomes in Advanced Clear Cell Gynecologic Cancer
October 22, 2022
Article
Patients with heavily pretreated clear cell gynecologic cancer achieved encouraging responses with single-agent pembrolizumab.
Pembrolizumab Continues to Boost Overall Survival in Patients with Head and Neck Cancer at 4-Year Follow-Up
October 21, 2022
Article
The overall survival benefit associated with pembrolizumab for patients with head and neck cancer continued to be observed at a 4-year follow-up of the KEYNOTE-048 trial.
Niraparib, Olaparib, and Rucaparib No Longer Available for Patients with Heavily Pretreated, BRCA-Mutated Advanced Ovarian Cancer
October 02, 2022
Article
Following potential safety concerns with 3 PARP inhibitors, manufactures have voluntarily elected to withdraw the indications for patients with heavily pretreated patients with BRCA-mutated ovarian cancer.